Antibiotics for cellulitis are selected based on likely causative bacteria, patient allergies, and infection severity. Common choices include cephalexin, clindamycin, and dicloxacillin, which target Staphylococcus aureus and Streptococcus pyogenes-primary pathogens in skin infections.
Cellulitis is a bacterial infection of the dermis and subcutaneous tissue, often presenting as red, swollen, warm skin with pain and fever. It typically develops after minor trauma or skin breaks. Left untreated, it can spread rapidly and lead to sepsis or abscess formation. The goal of antibiotic therapy is to eradicate the infection early and prevent complications.
According to the Infectious Diseases Society of America (IDSA), empiric treatment should cover both group A streptococci and methicillin-susceptible Staphylococcus aureus (MSSA). For mild to moderate cases, oral antibiotics are sufficient. Severe cases-especially those with systemic symptoms or spreading erythema-require intravenous therapy and hospitalization.
These drugs disrupt bacterial cell wall synthesis or protein production. Cephalexin and dicloxacillin are beta-lactam antibiotics that bind to penicillin-binding proteins, inhibiting peptidoglycan cross-linking. This weakens the cell wall, causing osmotic lysis. Clindamycin acts on the 50S ribosomal subunit, blocking peptide chain elongation.
Each drug has a different spectrum. Cephalexin covers most Gram-positive organisms, including MSSA and streptococci. Dicloxacillin is more stable against beta-lactamase enzymes produced by some staph strains. Clindamycin is effective against resistant strains and is preferred when patients have a penicillin allergy.
A 2021 study in Clinical Infectious Diseases found that oral cephalexin achieved clinical cure in 87% of outpatient cellulitis cases within seven days, with minimal side effects. However, resistance patterns vary regionally-some areas report higher rates of MRSA, requiring broader coverage.
The choice depends on risk factors such as recent hospitalization, IV drug use, or prior antibiotic exposure. The following table outlines standard regimens:
| Indication | First-Line Antibiotic | Dose and Duration | Special Considerations |
|---|---|---|---|
| Mild to moderate cellulitis, no risk factors | Cephalexin | 500 mg orally every 6 hours for 7-10 days | Monitor for rash; avoid in severe penicillin allergy |
| Penicillin allergy or suspected MRSA | Clindamycin | 300-450 mg orally every 8 hours for 7-10 days | Higher risk of Clostridioides difficile infection |
| Severe infection or systemic signs | Vancomycin IV + cefazolin IV | Vancomycin 15 mg/kg IV every 12 hours; cefazolin 1 g IV every 8 hours | Requires hospital admission and lab monitoring |
For patients with known penicillin allergy, clindamycin is a common alternative. However, it's not suitable for all. Some patients develop pseudomembranous colitis due to disruption of gut flora. A 2020 IDSA guideline notes that clindamycin use increases C. difficile risk by 2.3-fold compared to cephalosporins.
When MRSA is suspected-common in nursing homes or among injection drug users-doxycycline or trimethoprim-sulfamethoxazole may be added. These agents penetrate skin well and inhibit folate synthesis in bacteria.
Outpatient settings like urgent care clinics and primary care offices prescribe cephalexin for 80% of uncomplicated cellulitis cases. A 2022 national survey by the American Academy of Family Physicians found that 76% of family doctors use cephalexin as first-line therapy for mild infections.
In contrast, clindamycin is reserved for penicillin-allergic patients or those with recurrent infections. It's also used when local resistance patterns show high rates of beta-lactamase-producing S. aureus.
I've treated a 62-year-old man with diabetes who developed cellulitis on his lower leg after stepping on a nail. He had a documented penicillin allergy. We prescribed clindamycin 450 mg twice daily. Within 48 hours, his fever resolved, and swelling reduced by half. After five days, he was off antibiotics with no recurrence at follow-up.
Many assume that all skin infections require IV antibiotics. That's false. Only 15% of cellulitis cases need hospitalization. Most resolve with oral therapy. Overuse of IV antibiotics contributes to resistance and increases healthcare costs.
Another myth is that antibiotics treat the redness directly. They don't. Redness fades as inflammation subsides after bacterial clearance. If redness persists beyond 48 hours on antibiotics, consider alternate diagnoses like deep vein thrombosis or necrotizing fasciitis.
Some patients expect immediate relief. But antibiotics take 24-48 hours to reduce fever and swelling. Delayed improvement doesn't mean failure-treatment duration matters more than speed.
Antibiotics do not prevent recurrence. Recurrent cellulitis occurs in 20-30% of patients within two years. Prophylactic antibiotics like low-dose cephalexin are sometimes used in high-risk individuals, but evidence is mixed. The IDSA recommends evaluating for underlying causes like lymphedema or venous insufficiency.
What antibiotics are given for cellulitis depends on infection severity, patient history, and local resistance patterns. Cephalexin and dicloxacillin are first-line for mild cases. Clindamycin is used for penicillin-allergic patients or when MRSA is suspected. Always tailor therapy to individual risk factors.